Biolife solutions stock.

BioLife recently disclosed its financial results for the fourth quarter of 2022, showcasing solid revenue growth and a better gross margin. In Q4 2022, the company brought in $44.3 million in ...

Biolife solutions stock. Things To Know About Biolife solutions stock.

BioLife Solutions Reports First Quarter 2023 Financial Results. Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%. Q1 2023 ...msn.com - November 17 at 10:30 PM. BioLife Solutions (BLFS) was Impacted by Inventory Destocking and Elongated Sales Cycles. finance.yahoo.com - November 16 at 10:07 AM. Analysts Just Shaved Their BioLife Solutions, Inc. (NASDAQ:BLFS) Forecasts Dramatically. finance.yahoo.com - November 16 at 10:07 AM.Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] Solutions: Overcoming Challenges and Primed for Growth – An Optimistic Buy Recommendation Amid Revenue Surpassing Expectations and Anticipated Divestiture TipRanks 18dNov 27, 2023 · BioLife Solutions Stock Performance. BLFS stock opened at $14.08 on Monday. The business has a 50 day moving average of $12.13 and a 200-day moving average of $16.47. BioLife Solutions, Inc. has a 12-month low of $8.92 and a 12-month high of $26.89. The firm has a market cap of $619.96 million, a PE ratio of -5.94 and a beta of 1.57.

BOTHELL, Wash., Jan. 10, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced preliminary revenue for the fourth quarter and full year 2021.BOTHELL, Wash., Aug. 9, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has entered into a definitive agreement to acquire all remaining outstanding shares of privately held Sexton ...The estimated net worth of Aby J. Mathew is at least $3.52 million as of November 13th, 2023. Dr. Mathew owns 275,726 shares of BioLife Solutions stock worth more than $3,521,021 as of November 18th. This net worth estimate does not reflect any other assets that Dr. Mathew may own.

Rhumbline Advisers decreased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS – Free Report) by 8.1% in the second quarter, Holdings Channel.com …

BioLife Solutions is updating 2023 revenue guidance, which is based on expectations for its existing business. Total revenue for 2023 is expected to range from $144 million to $158 million ...With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted Net Income per share basis (Non-GAAP) in ...The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 10.89% during the next 3 months and, with a 90% probability hold a price between $0.00000328 and $0.0002 at the end of this 3-month period.Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

We are revolutionizing regenerative medicine, biobanking and drug discovery by increasing the viability of biologics. BioLife Solutions is a class-defining cell and gene therapy bioproduction tools and services company. Our solutions give life science companies and clinical researchers significant improvement in shelf life and post-preservation ...

Which BioLife Solutions insiders have been buying company stock? The following insider purchased BLFS shares in the last 24 months: Casdin Partners Master Fund, L ($12,648,274.13). How much insider buying is happening at BioLife Solutions?

10 nov 2023 ... Byrnes covers the Healthcare sector, focusing on stocks such as Durect, Oncternal Therapeutics, and BioLife Solutions. According to TipRanks, ...Consensus BioLife Solutions, Inc. Equities. BLFS. US09062W2044. Market Closed - Nasdaq. Other stock markets.BioLife Solutions, Inc. (BLFS) Stock Price, News, Quote & History - Yahoo Finance Canada markets close in 5 hours 5 minutes S&P/TSX 20,174.44 +60.48(+0.30%) S&P …Water bath, 37°C CryoStor CD10 (BioLife Solutions, 210102) Scalpel Surgical forceps, scissors 70um strainer (ex. Sigma, CD1-1KT) RPMI 1640 (Invitrogen 11875-093) 50ml conical DNase I (Roche, 10-104-159-001, ... 7. Add 100uL Liberase TL (stock 5mg/mL) to each tube, for final 100ug/mL 8. Macerate the tissues with gentleMACS using the …Nov 8, 2023 · Biolife Solutions releases figures for Q3 on November 9. Wall Street analysts predict losses per share of $0.364. Go here to track Biolife Solutions stock price in real-time ahead of earnings. BOTHELL, Wash., Nov. 4, 2021 / PRNewswire / -- BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced changes to its executive management team, effective immediately.

BioLifeSolutions, Inc. (NASDAQ:BLFS – Get Rating) COO Greef Roderick De sold 1,500 shares of the stock in a transaction dated Wednesday, November 16th. The shares were sold at an average price of $2Consensus BioLife Solutions, Inc. Equities. BLFS. US09062W2044. Market Closed - Nasdaq. Other stock markets.BioLife Solutions is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. Learn why I rate BLFS stock a hold.BOTHELL, Wash., Nov. 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the three and nine months …BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2023 Earnings Call Transcript November 9, 2023 BioLife Solutions, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.38. Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2023 Shareholder and …

BOTHELL, Wash., Sept. 1, 2021 / PRNewswire / -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies ...

BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets.BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to break-even earnings per share a year ago.BioLife recently disclosed its financial results for the fourth quarter of 2022, showcasing solid revenue growth and a better gross margin. In Q4 2022, the company brought in $44.3 million in ...Biolife Solutions Inc (NASDAQ:BLFS) has a beta value of 1.60 and has seen 2.24 million shares traded in the last trading session. The company, currently valued at $596.91M, closed the last trade at $13.25 per share which meant it gained $0.88 on the day or 7.11% during that session. The BLFS stock ...See the latest BioLife Solutions Inc stock price (BLFS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Jun 26, 2020 · Hedge fund activity in BioLife Solutions, Inc. (NASDAQ:BLFS) Heading into the second quarter of 2020, a total of 9 of the hedge funds tracked by Insider Monkey were long this stock, a change of ... Nov 9, 2023 · BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets. BioLife Solutions, Inc. : News, information and stories for BioLife Solutions, Inc. | Other OTC: | Other OTC

BioLife Solutions (BLFS) In a report released today, Robert Wasserman from Benchmark Co. maintained a Hold rating on BioLife Solutions. The company’s shares closed last Thursday at $11.96.

–BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the fourth quarter and year ended December 31, 2022.

Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] the latest BioLife Solutions Inc (BLFS) stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's financial performance, balance sheet, cash flow, and earnings per share for the fiscal Q2 2023 ended 6/30/23.Mar 16, 2023 · BioLife Solutions is reaffirming 2023 revenue guidance, which is based on expectations for its existing business. Total revenue for 2023 is expected to range from $188 million to $202 million ... Nov 8, 2023 · Biolife Solutions releases figures for Q3 on November 9. Wall Street analysts predict losses per share of $0.364. Go here to track Biolife Solutions stock price in real-time ahead of earnings. Mar 23, 2023 · BioLife Solutions Reports Third Quarter 2023 Financial Results. BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of biopreservation media and other cell processing tools and biostorage services for the cell and gene... Nov 02, 2023. SenseAnywhere: Cloud-based Monitoring Solutions. Users can connect any number of refrigerators, ULT freezers, and cryogenic freezers to view performance data in one SenseAnywhere account. SenseAnywhere is 21 CFR part 11 compliant and EN12830-2018. Users can download temperature records for audit trail purposes and Good …Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] December 15, 2022, BioLife Solutions, Inc. (NASDAQ:BLFS) stock closed at $18.77 per share. One-month return of BioLife Solutions, Inc. (NASDAQ:BLFS) was -11.46%, and its shares lost 48.63% of ...You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Nov 17, 2023 · Open 18.44. Day High 18.95. Day Low 18.17. Prev Close 18.25. 52 Week High 26.96. 52 Week High Date 09/08/22. 52 Week Low 10.40. 52 Week Low Date 05/12/22. Market Cap 812.385M.

Oct 16, 2023 · BioLife Solutions to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 16, 2023. BOTHELL, Wash. , March 9, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and... The current stock price of is . Chart and price action Where to buy Biolife Solutions shares? Does not pay dividends in 2023. Prediction and analyst recommendations.A high-level overview of BioLife Solutions, Inc. (BLFS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …The estimated net worth of Roderick de Greef is at least $463,582.14 as of November 30th, 2022. Mr. de Greef owns 34,314 shares of BioLife Solutions stock worth more than $463,582 as of November 20th. This net worth estimate does not reflect any other investments that Mr. de Greef may own.Instagram:https://instagram. shy yieldchart industries inclithium battery stockroblox stoxk The corporate mailing address for Ms. Aebersold and other BioLife Solutions executives is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. BioLife Solutions can also be reached via phone at (425) 402-1400 and via email at [email protected]. Learn More on Sarah Aebersold's contact information.Rhumbline Advisers decreased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS – Free Report) by 8.1% in the second quarter, Holdings Channel.com … what is the most valuable state quarterchase bank refinance rates BioLife Solutions: Overcoming Challenges and Primed for Growth – An Optimistic Buy Recommendation Amid Revenue Surpassing Expectations and Anticipated DivestitureBioLife Solutions Inc stock performance at a glance. Check BioLife Solutions Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. nso malpractice insurance reviews BLFS BioLife Solutions, Inc. Earnings Date & History. Follow. $13.250.88 (+7.11%)4:00 PM 12/01/23. NASDAQ | $USD | Post-Market: $13.25 4:55 PM.BioLife Solutions Reports First Quarter 2023 Financial Results. Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%. Q1 2023 ...BioLife Solutions is reaffirming 2023 revenue guidance, which is based on expectations for its existing business. Total revenue for 2023 is expected to range from $188 million to $202 million ...